Holiday Sale | Save 50%
SubscribeLogin
Holiday Sale | Save 50%
Published

Ozempic and Wegovy could double as kidney disease treatment, study suggests

  • The FLOW study involved 3,533 patients and showed a 24% decrease in kidney disease progression and cardiovascular and kidney death after 3.4 years.
  • Patients treated with semaglutide had slower kidney function decline, 18% lower risk of major cardiovascular events, and 20% lower risk of death compared to those on a placebo.
  • Semaglutide use in type 2 diabetes patients with chronic kidney disease reduces major kidney outcomes and risk of cardiovascular events, as stated by Perkovic.
Insights by Ground AI
Does this summary seem wrong?
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 83% of the sources are Center
84% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

DiabetesDiabetes
WegovyWegovy
ObesityObesity
HealthHealth
ScienceScience
OzempicOzempic
MedicalMedical
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal